Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC


Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Ticiana A. Leal, MD, medical oncologist, ​team leader, University of Wisconsin Carbone Cancer Center Thoracic Malignancies Disease Oriented Team, assistant professor, Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin ​School of Medicine and Public Health, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer (ES-SCLC). 

​Ultimately, the goal of the study was to improve therapy for patients with ES-SCLC, says Leal.

Notably, the randomized, cooperative group study began in 2017 when immunotherapy was added to platinum-based chemotherapy, in an attempt to boost tumor immunity.

This trial evaluate​d standard cisplatin/carboplatin and etoposide with or without the checkpoint inhibitor nivolumab (Opdivo) in the frontline setting for patients with ES-SCLC, Leal concludes.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,